BCL2 and autoimmune disease: The anti-apoptotic Bcl-2 family inhibitor ABT-263 targets Bcl-2, Bcl-XL, and Bcl-w to modulate the apoptotic threshold of lymphocytes, potentially aiding in the clearance of aberrant lymphocytes in autoimmune diseases (104).